Xencor | XNCR - Assets


Xencor reported $724.96M in Assets for its fiscal quarter ending in June of 2026.





Assets Change Date
AbbVie USD 135.12B 1.35B Jun/2026
Alnylam Pharmaceuticals USD 5.56B 429.22M Jun/2026
Amgen USD 95.64B 3.14B Jun/2026
Arrowhead Research USD 2.11B 156.25M Jun/2026
AstraZeneca USD 115.83B 1.82B Jun/2026
Biogen USD 32.09B 2.6B Jun/2026
Bristol-Myers Squibb USD 87.63B 1.16B Jun/2026
Cytokinetics USD 1.92B 651.07M Jun/2026
GlaxoSmithKline GBP 61.74B 1.13B Jun/2026
J&J USD 201.06B 167M Jun/2026
Karyopharm Therapeutics USD 131.42M 23M Mar/2026
MacroGenics USD 345.41M 127.54M Jun/2026
Merck USD 129.8B 1.12B Jun/2026
Novartis USD 122.03B 3.5B Jun/2026
Pfizer USD 201.13B 6.49B Jun/2026
Regeneron Pharmaceuticals USD 41.73B 861.8M Jun/2026
Roche Holding CHF 98.2B 2.5B Jun/2026
Xencor USD 724.96M 11.89M Jun/2026